K. Shogen

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
K Shogen, K. Shogen, Kuslima Shogen
Publication record
57 papers · 2,194 citations · H-index 27

PAPERS

Crystal structure of Onconase at 1.1 Å resolution – insights into substrate binding and collective motion
201115 citationsauthor #3
Onconase, atomic resolution crystal structure
20110 citationsauthor #3
Physiological and Molecular Role of Ranpirnase on Cancer Treatment
20100 citationsauthor #4
Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent
201035 citationsauthor #7
Local Controlled Delivery of Anti-Neoplastic RNAse to the Brain
200910 citationsauthor #5
Effect of Onconase on double-stranded RNA in vitro.
200926 citationsauthor #3
Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM).
200922 citationsauthor #8
Activity of Anti-Tumor Endoribonucleases, Onconase (ranpirnase) and R-Amphinase in Chronic Lymphocytic Leukemia
20082 citationsauthor #4
Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer
20089 citationsauthor #2
Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
2008106 citationsauthor #2
The inhibition of radiation repair by ranpirnase ± l-buthionine sulfoximide on lung cancer
20080 citationsauthor #6
Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines
200842 citationsauthor #6
Ex Vivo Cytotoxic Activity of Endoribonucleases, Onconase (ranpirnase) and R-Amphinase, against Acute Myeloblastic Leukemia Cells
20083 citationsauthor #6
The cytotoxic ribonuclease onconase targets RNA interference (siRNA)
200842 citationsauthor #4
The interdependence between catalytic activity, Conformational stability and cytotoxicity of onconase
200717 citationsauthor #5
Onconase, an anti-tumor ribonuclease suppresses intracellular oxidative stress.
200731 citationsauthor #10
Cytostatic and Cytotoxic Properties of Amphinase: A Novel Cytotoxic Ribonuclease from Rana pipiens Oocytes
200722 citationsauthor #5
The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer.
200718 citationsauthor #5
Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with onconase.
200720 citationsauthor #3
Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice.
200735 citationsauthor #4
Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes.
200729 citationsauthor #8
Towards personalized medicine: Establishment and in vivo characterization of a low passage tumor xenograft tumor predictive of clinical response
20070 citationsauthor #6
Possible mechanisms of improved radiation response by cytotoxic RNase, Onconase, on A549 human lung cancer xenografts of nude mice.
200714 citationsauthor #6
The Therapeutic Mechanisms of Enhancement of Radiation Response on Lung Cancer by Ranpirnase
20071 citationsauthor #7
Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells.
200747 citationsauthor #8
2668 : The Physiological Mechanisms of Ranpirnase-Induced Enhancement in Radiation Response on A549 Human Non-Small Cell Lung Carcinoma Xenografts in Nude Mice
20062 citationsauthor #6
The Enhanced Efficacy of Cisplatin and Carboplatin by the Cytotoxic RNase, Onconase, on A549 Human Lung Cancer Xenografts of Nude Mice
20050 citationsauthor #4
Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB.
200428 citationsauthor #5
ONCONASE® and Its Therapeutic Potential
200324 citationsauthor #2
Effect of ONCONASE +/- tamoxifen on ASPC-1 human pancreatic tumors in nude mice.
200328 citationsauthor #4
Entry into Cells and Selective Degradation of tRNAs by a Cytotoxic Member of the RNase A Family*
2002101 citationsauthor #5
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
2002166 citationsauthor #11
Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase).
200222 citationsauthor #6
Phase I I T rial o f a S ingle W eekly I ntravenous D ose o f Ranpirnase i n P atients W ith U nresectable M alignant Mesothelioma
20020 citationsauthor #11
Amino Acid Sequence of an Anti-tumor Protein from Rana pipiens Oocytes and Early Embryos
200126 citationsauthor #3
Tumoricidal effects of Onconase on various tumors
200038 citationsauthor #6
Enhanced cellular radiation sensitivity of androgen-independent human prostate tumor cells by onconase.
200014 citationsauthor #5
Induction of differentiation of leukaemic (HL‐60) or prostate cancer (LNCaP, JCA‐1) cells potentiates apoptosis triggered by onconase
200024 citationsauthor #6
2037 Enhanced radiation sensitization by cellular and physiological roles of onconase(r)
19990 citationsauthor #6
Potentiation of tumor necrosis factor induced apoptosis by onconase.
199850 citationsauthor #6
G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation
199868 citationsauthor #5
Inhibition of HIV-1 Production and Selective Degradation of Viral RNA by an Amphibian Ribonuclease*
199693 citationsauthor #5
2214 Onconase-induced changes in radiation response and physiological parameters in solid tumors
19960 citationsauthor #3
Relationship between response rate and median survival in patients with advanced nonsmall cell lung-cancer - comparison of onconase(r) with other anticancer agents.
199530 citationsauthor #6
ONCONASE(ONC), A PROTEIN USED FOR THE THERAPY OF PATIENTS WITH ADVANCED PANCREATIC CANCER (PC): A PHASE I/II TRIAL
19940 citationsauthor #7
Toxicity of an antitumor ribonuclease to Purkinje neurons
199451 citationsauthor #5
Phase-I human clinical-trial of onconase(r) (p-30 protein) administered intravenously on a weekly schedule in cancer-patients with solid tumors.
199371 citationsauthor #4
Human tumor-cell growth modulatory effects of the aebs/hic-binding drugs used as single agents and in combination with a novel amphibian oocyte rnase.
19932 citationsauthor #3
Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines.
199255 citationsauthor #4
Invitro synergism between a novel amphibian oocytic ribonuclease (onconase(r)) and tamoxifen, lovastatin and Cisplatin, in human ovcar-3 ovarian-carcinoma cell-line.
199230 citationsauthor #3
Comparative molecular modeling and crystallization of P‐30 protein: A novel antitumor protein of Rana pipiens oocytes and early embryos
199219 citationsauthor #5
Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases.
1991227 citationsauthor #3
Carcinoma of the esophagus: CT vs MR imaging in determining resectability.
1991161 citationsauthor #9
Striking Increase of Survival of Mice Bearing M 109 Madison Carcinoma Treated With a Novel Protein From With a Novel Protein From Amphibian Embryos
199073 citationsauthor #3
Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos.
199045 citationsauthor #3
Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P‐30 protein, a novel protein possessing anti‐tumour activity
199052 citationsauthor #5
Cytostatic and Cytotoxic Effects of Pannon (P‐30 Protein), A Novel Anticancer Agent
1988148 citationsauthor #5

TIMELINE

1988 148 citations

1990 170 citations

1991 388 citations

1992 104 citations

1993 73 citations

1994 51 citations

1995 30 citations

1996 93 citations

1998 118 citations

1999 0 citations

2000 76 citations

2001 26 citations

2002 289 citations

2003 52 citations

2004 28 citations

2005 0 citations

2006 2 citations

2007 234 citations

2008 204 citations

2009 58 citations

2010 35 citations

2011 15 citations

K. Shogen

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT